… There is probably little or no difference between most vaccines and placebo for serious …
of COVID‐19 vaccines, and this review is updated regularly on the COVID‐NMA platform (covid-…

… mass vaccination plans for the population. This study evaluated the safety and effectiveness
of the COVID-19 vaccine … analysis for the published COVID-19 vaccine clinical trial results. …

… aspects of designing any vaccine. One of the concerns posed during the production of the
COVID-19 vaccine was whether the immune responses evidenced by the vaccine will help or …

… To estimate the efficacy of the COVID-19 vaccines, we evaluated all the COVID-19 vaccine
data that have been published from phase III clinical trials; a total of 194,015 cases were …

… terms for “COVID-19 vaccine safety monitor/monitoring/surveillance” and the names of
countries with COVID-19 vaccine programs to identify their available safety surveillance data. …

… of these vaccines are beyond the scope of this review. The Janssen’s COVID-19 vaccine has
not … very recently and vaccination campaigns will not start until mid-April 2021 at best. Other …

… vaccines are safe and effective in this population? Here we briefly review the main candidate
vaccines, with a focus on the evidence of their safety … of the main COVID-19 vaccines being …

… As we well know from extensive experience, vaccine safety issues can threaten not only the
success of any COVID-19 vaccine programme but also routine immunisation programmes. It …

… to assess vaccine efficacy after a single dose, NVX-CoV2373 provided levels of protection
after the first dose in a range similar to those of other Covid-19 vaccines. The favorable safety …

… people receiving candidate COVID-19 vaccines to understand … the COVID-19 vaccine
candidates with respect to safety at this … enhanced severity of COVID-19 disease, after vaccination. …